â€œMarket withdrawalsâ€•of medicines in Germany af and clinical guideline recommendations

Health Economics Review

8, 23

DOI: 10.1186/s13561-018-0209-3

Citation Report

#	Article	IF	Citations
3	Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data. Journal of Evidence-Based Medicine, 2019, 12, 9-15.	2.4	3
4	Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree. Health Economics Review, 2019, 9, 35.	0.8	6
5	A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-15.	0.7	0
6	Zehn Jahre AMNOG â€“ RÃ¼ckblick und Ausblick aus Sicht der Arzneimittelkommission der deutschen Ã„rzteschaft. , 2020, , 185-200.		6
8	Multicenter, crossâ€sectional study of the costs of illness and costâ€driving factors in adult patients with epilepsy. Epilepsia, 2022, 63, 904-918.	2.6	20
9	How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?. Applied Health Economics and Health Policy, 2022, 20, 287-290.	1.0	3
10	Does health technology assessment compromise access to pharmaceuticals?. European Journal of Health Economics, 2023, 24, 437-451.	1.4	2
12	Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries. Pharmacoeconomics, 2022, 40, 1131-1142.	1.7	2
13	Health App by Prescription: The German Nation-Wide Model. , 2022, , 63-79.		0
14	QualitÃt der Arzneimittelversorgung â€“ Theoretischer und konzeptueller Rahmen. , 2022, , 13-29.		0